

ANTITRUST NOTICE

As members of the Workers' Compensation Insurance Rating Bureau of California (WCIRB) and their agents, you are bound, when involved in meetings, presentations, webinars or other activities of the WCIRB, to limit your actions (as well as discussions and virtual chats, other than social ones) to matters relating to the business of the WCIRB. Matters that do not relate directly to WCIRB business should be avoided. Members and their agents should particularly avoid discussions, chats or conduct that could be construed as intended to affect competition (or access to markets). Thus, as members and their agents, you should not discuss or pursue the business interests of individual insurers or others, including, in particular, the plans of individual members involving, or the possibility or desirability of (a) raising, lowering, or stabilizing prices (premiums or commissions); (b) doing business or refusing to do business with particular, or classes of, insurers, reinsurers, agents, brokers, or insureds, or in particular locales; or (c) potential actions that would affect the availability of products or service either generally or in specific markets or locales.

NOTICE & COPYRIGHT

This presentation was developed by the Workers' Compensation Insurance Rating Bureau of California (WCIRB) for informational purposes only. The WCIRB shall not be liable for any damages of any kind, whether direct, indirect, incidental, punitive or consequential, arising from the use, inability to use, or reliance upon information provided in this presentation.

© 2022 Workers' Compensation Insurance Rating Bureau of California. All rights reserved.

No part of this work may be reproduced or transmitted in any form or by any means, electronic or mechanical, including, without limitation, photocopying and recording, or by any information storage or retrieval system without the prior written permission of the Workers' Compensation Insurance Rating Bureau of California (WCIRB), unless such copying is expressly permitted in this copyright notice or by federal copyright law. No copyright is claimed in the text of statutes and regulations quoted within this work.

Each WCIRB member company, including any registered third party entities, (Company) is authorized to reproduce any part of this work solely for the following purposes in connection with the transaction of workers' compensation insurance: (1) as necessary in connection with Company's required filings with the California Department of Insurance; (2) to incorporate portions of this work, as necessary, into Company manuals distributed at no charge only to Company employees; and (3) to the extent reasonably necessary for the training of Company personnel. Each Company and all agents and brokers licensed to transact workers' compensation insurance in the state of California are authorized to physically reproduce any part of this work for issuance to a prospective or current policyholder upon request at no charge solely for the purpose of transacting workers' compensation insurance and for no other purpose. This reproduction right does not include the right to make any part of this work available on any website or any form of social media.

Workers' Compensation Insurance Rating Bureau of California, WCIRB, WCIRB California, WCIRB Connect, WCIRB Inquiry, WCIRB CompEssentials, X-Mod Direct, eSCAD, Comprehensive Risk Summary, X-Mods and More, Annual Business Comparative and the WCIRB California logo (WCIRB Marks) are registered trademarks or service marks of the WCIRB. WCIRB Marks may not be displayed or used in any manner without the WCIRB's prior written permission. Any permitted copying of this work must maintain any and all trademarks and/or service marks on all copies.

To seek permission to use any of the WCIRB Marks or any copyrighted material, please contact the WCIRB at customerservice@wcirb.com.

Table of Contents/Agenda

- 1. AC16-06-05: Update on Medical Severity Trends by Component
- 2. AC22-03-01: First Quarter 2022 Review of Diagnostics
- 3. AC22-04-04: Retrospective Evaluation of 2021 Medical Fee Schedule Changes
- 4. AC22-03-02: 12/31/2021 Experience Review
- 5. AC22-04-03: 9/1/2022 Filing COVID-19 Claim Cost Projection
- 6. AC22-04-01: 9/1/2022 Filing Loss Adjustment Expense Experience Review



Update on Medical Severity Trends by Component



Summary of Medical Severity Trends through 2021

As of February 28, 2022

Data Source


- Based on medical transaction data through 2021 (2021Q4 data preliminary, based on 2/3 of the market)
- COVID-19 claims were excluded

Key Findings

- Overall medical severity per claim: +11% in 2020 and +6% in 2021
 - Increase in 2020 mostly driven by a shift in claim mix related to the pandemic
 - Increase in 2021 mostly driven by the 2021 fee schedule changes (medical-legal and E/M office visits)
- Number of telemedicine services per claim dropped slightly (-14%) in 2021 from the peak (>+4300%) in 2020
- Pharmaceutical paid per claim declined in 2021 (-10%) after a temporary increase (+8%) in the pharma costs in 2020



Share of Total Medical Payments by Service Type







^{*} HCPCS stands for Healthcare Common Procedure Coding System. HCPCS codes primarily include ambulance services, durable medical equipment, prosthetics, orthotics, and supplies used outside a physician's office, home health services, and interpreter services.


Source: WCIRB medical transaction data collected beginning in the third quarter of 2012. COVID-19 claims were excluded from the analysis.

% Change in All Medical Services Cost per Claim

As of February 28, 2022











Source: WCIRB medical transaction data collected beginning in the third quarter of 2012. COVID-19 claims were excluded from the analysis and the exclusion applies to all subsequent slides.

% Change in *Evaluation & Management* Cost per Claim (20% of All Medical Payments)












% Change in *Telemedicine* Cost per Claim (1.7% of All Medical Payments)

As of February 28, 2022












Note: For telemedicine services after March 1, 2020, only services from CMS list of telehealth services are included pursuant to the DWC rules.

% Change in *Pharmaceutical* Cost per Claim (3.1% of All Medical Payments)

As of February 28, 2022












% Change in *Opioid* Cost per Claim (0.2% of All Medical Payments)

As of February 28, 2022











% Change in *Inpatient* Cost per Claim (episode-based) (11% of All Medical Payments)

As of February 28, 2022











% Change in *Medical-Legal* Cost per Claim (14% of All Medical Payments)

As of February 28, 2022









02

First Quarter 2022 Review of Diagnostics




Distribution of Estimated Ultimate Number of Claims by Injury Type (Exhibit M4)

Category


Distribution of Ultimate Number of All Claims


Injury Type


- Medical Only
- Permanent Indemnity
- ☐ Temporary Indemnity

















Claim Count Ratios by Region Based on Unit Statistical Data at 1st Report Level (Exhibit C17)



Accident Year

2017

2020

Region


All Other


All Regions


Bay Area

Los Angeles/LA Basin

San Diego







03

Retrospective Evaluation of 2021 Medical Fee Schedule Changes



Background on 2021 Official Medical Fee Schedule (OMFS) Adjustments to Evaluation and Management Services

- The Division of Workers' Compensation (DWC) adopted changes to reimbursement allowance made by the Centers for Medicare & Medicaid Services (CMS) for Evaluation/Management (E/M) services effective March 1, 2021.
- In April 2021, the WCIRB conducted a prospective evaluation of the cost impact of increased reimbursement allowance for E/M office/outpatient visit services and estimated an increase of 15%* to the E/M office visit costs. The cost impact was reflected in the September 1, 2021 Advisory Pure Premium Rate Filing.
- The WCIRB has conducted a retrospective evaluation of the cost impact of the changes to the E/M service reimbursement allowance based on actual post-schedule change payment patterns.



Data Source and Summary of Key Preliminary Findings

As of February 28, 2022

Data Source

- Based on WCIRB medical transaction data for service years 2019 to 2021
 - Focused on E/M office visit services between March and December for each service year
 - COVID-19 claims were excluded

Key Preliminary Findings

- Average paid per E/M office visit transaction increased by 10%* in 2021 compared to 2019, slightly lower than the projected increase of 15%
- Mix of E/M office services remained similar in 2021 compared to 2019, but the network discounting appeared to be larger in 2021
- Number of E/M office visits per claim increased by 4% in 2021, likely not related to the March 1, 2021 fee schedule update



E/M Office Visit Services – Percent Change in Paid per Transaction 2021 Compared to 2019 (March – December)

E/M Office Visit code	Description	Share of E/M Transactions in 2021	Share of E/M Payments in 2021	% Change in Paid Per Transaction (2021 vs. 2019)
99202	New sf 15-29 min	1%	0%	-1%
99203	New low 30-44 min	7%	7%	6%
99204	New mod 45-59 min	8%	11%	6%
99205	New hi 60-74 min	2%	3%	12%
99211	Established minimal prob	0%	0%	-10%
99212	Established sf 10-19 min	3%	1%	23%
99213	Established low 20-29 min	35%	26%	22%
99214	Established mod 30-39 min	32%	32%	17%
99215	Established hi 40-54 min	4%	6%	23%
99202-99215	All 9 Codes Combined	91%	86%	15%*





Actual Cost Increases in the E/M Office Visit Services 2021 Compared to 2019 (March – December)

E/M Office Visit (99202-99205, 99211-99215)	Actual 2019	Actual 2020	Actual 2021	Actual 2021 vs. Actual 2019
Paid per Transaction	\$124	\$125	\$143	15%
Average Network Discounting	12%	13%	15%	-
Transactions per 100 Claims (likely not related to the fee schedule update)	338	346	351	4%
Paid per Claim	\$419	\$432	\$504	20%



Cost Impact of the 2021 Fee Schedule Changes to the E/M Office Visit Services – Preliminary Finding

2021 Compared to 2019 and 2020 (March – December)

E/M Office Visit (99202-99205, 99211-99215)	Projected 2021 (compared to 2019 payment)	Actual 2021 (compared to 2019 payment)	Actual 2021 (compared to 2020 payment)
Percentage Change in Paid per Transaction	20%	15%	15%
Removing Typical Annual Inflationary Change **	2.5% * 2 years	2.5% * 2 years	2.5% * 1 year
Cost Impact Estimate	15%	10%	12.5%



Background on New Medical-Legal Fee Schedule

- The Division of Workers' Compensation (DWC) adopted significant changes to the Medical-Legal (ML) Fee Schedule effective April 1, 2021.
- The new ML Fee Schedule is intended to increase the reimbursement allowance for medical-legal reports while eliminating complexity factor overlay onto reimbursement allowances.
- In April 2021, the WCIRB conducted a prospective evaluation of the cost impact of new ML Fee Schedule and estimated an increase of 22% to medical-legal costs. The cost impact was reflected in the September 1, 2021 Advisory Pure Premium Rate Filing.
- The WCIRB has conducted a retrospective cost impact evaluation of the new ML Fee Schedule based on the actual payments in 2021.



April 1, 2021 ML Fee Schedule – Summary of Key Changes

- Increases fees for relative value (RV) from \$12.5 to \$16.25
- Adds a reimbursement allowance for missed appointments
- Changes to modifiers
 - Agreed Medical Evaluator (AME), interpreter, psychologist/psychiatrist, toxicologist and oncologist ML services
- Replaces the time component in the ML evaluation codes (old ML101, ML104 and ML106) with a separate record review procedure code for complexity factor
- Adds a ML code for sub rosa recordings review

Pre-4/1/21 ML Code	New ML Code	Procedure Description	
ML100	ML200	Missed Appointment for a Comprehensive or Follow-Up Medical-Legal Evaluation	
ML102			
ML103	ML201	201 Comprehensive Medical-Legal Evaluation	
ML104			
ML101	ML202	Follow-up Medical-Legal Evaluation	
ML106	ML203	Fees for Supplemental Medical-legal Evaluations	
ML105	ML204	Fees for Medical-Legal Testimony	
	ML205	Fees for Review of Sub Rosa Recordings	
	MLPRR	Record Review (applicable to ML200-ML203)	



Data Source and Summary of Key Preliminary Findings

Data Source

- Based on the WCIRB medical transaction data from service year 2018 through 2021
- Compared ML services provided from Q2 through Q4 of 2021 to those in 2019
- COVID-19 claims were excluded


Key Preliminary Findings

- Under the new ML Fee Schedule, ML payment per claim in 2021 was 39% higher than in 2019. The actual cost impact is higher than the projected (+22%).
 - Record review appears to be a key cost driver (25% of 2021 ML payments, higher than projected 9%)
- Including record review, paid per ML service increased by 38% in 2021 compared to those in 2019
- Overall, number of ML services per claim remained the same in 2021
 - Number of follow-up evaluations per claim increased significantly, while the number of comprehensive and supplemental evaluations decreased



Projected vs. Actual Distribution of Payments for Medical-Legal Services (Q2 through Q4)







Projected vs. Actual Record Reviews for Additional Pages* (2021Q2 through Q4)

As of February 28, 2022


	Share of ML Services with Additional Pages for Record Review	Average Number of Additional Pages	Average Paid For Record Review
Missed Appointment	6%	688	\$2,063
Comprehensive	42%	583	\$1,750
Follow-up Eval	23%	424	\$1,273
Supplemental	29%	421	\$1,262
Record Review Only (2% of all record review)	N/A	507	\$1,520
Overall	32%	526	\$1,577

Lower than projected 62%

5X higher than projected \$263



Quarterly Trend of Average Payment for Medical-Legal Services including Record Review





Comparison of ML Services in 2021 to Those in 2019 (Q2 through Q4) – Preliminary Findings

As of February 28, 2022

ML Service	Mix of ML Services in 2021	Actual 2021 Compared to Actual 2019			
		% Change in Paid per ML Service*	% Change in ML Services* per Claim	% Change in ML Paid per Claim	
Missed Appointment	8%	+85%	+34%	+147%	
Comprehensive	46%	+51%	-11%	+33%	
Follow-up Eval	13%	+ 7%	+117%	+133%	
Supplemental	30%	+30%	-14%	+12%	
Testimony	1%	+36%	+69%	+130%	
Overall	100%	+38%	0%	+39%	

Higher than Projected Change of +22%




Comparison of Actual and Projected Cost Impact of New Medical-Legal Fee Schedule – Preliminary Findings

Comparison of Percentage Change in Actual Paid per Claim and in Estimated Paid per Claim

Projected 2021 to Actual 2019

Actual 2021 to Actual 2019

Incremental Cost Impact (Actual vs. Projected)





04

12/31/2021 Experience Review




Updated Summary of 12/31/2021 Experience (Excluding COVID-19)

- 100% of market included
- Updates from 3/21/2021 meeting review:
 - Additional insurer data submissions and revisions
 - Loss development primarily based on latest year paid adjusted for changes in claim settlement rates and reforms
 - Adjustment to medical development for 2021 fee schedule changes updated based on retrospective evaluation
 - Projected adjustment to weekly TD maximum updated to reflect projected wage changes
 - Projected changes in average wages adjusted based on 3/21/2021 discussion
 - Projected frequency trends adjusted based on 3/21/2021 discussion
 - Projected loss ratio is trended from AY 2019 and 2021
- Projected loss ratio using 4/14/22 Agenda preliminary methodologies is 0.568
 - Decrease from 9/1/21 Filing (0.596) primarily driven by frequency projections and wage forecasts
- Updated loss ratio based on staff recommendations of 0.606 is slightly above 9/1/21 Filing projection




12/31/2021 Experience Review

Developed Indemnity Loss Ratios (Exhibit 3.1)





Developed Medical Loss Ratios (Exhibit 3.2)





Alternative Loss Development Methodologies (Item AC22-04-02) Incurred Methods

- Unadjusted Incurred Projections
 - Best with stable case reserve levels and incurred patterns
 - Can be distorted by changing reserve levels
 - ★ Incurred development more volatile and cyclical than paid development
 - ★ Performed poorly during transition periods
 - Greater variability across insurers than paid method
 - ★ Difficult to impute reform adjustments
 - Treatment of MCCP in medical reserves unknown
 - ★ Incurred projections continue to be well below paid projections
- Incurred Adjusted for Changes in Case Reserve Levels
 - Best with clear evidence of changing case reserve levels
 - Unclear how to impute reform impacts
 - Recent updates reduced reliance on assumptions and improved accuracy of adjustment
 - ★ Method can be very volatile with constantly shifting reserve levels (3-year average is used)
 - ★ Pandemic volatility in claim activity may result in additional volatility in this approach




Alternative Loss Development Methodologies (Item AC22-04-02) Paid Methods

- Unadjusted Paid Projections
 - Best with stable payment patterns
 - Can be distorted by changing settlement rates or reforms
 - ★ Generally outperformed unadjusted incurred during transition periods
 - Less variability in paid patterns across insurers than in incurred patterns
 - ★ Recent changes in paid development likely related to reforms and claim settlement changes
- Reform-Adjusted Paid
 - Best with clear evidence of reform impact on payment patterns
 - ★ Adjustments for SB 1160 (liens) and pharmaceutical cost changes reviewed in December 2021
 - ★ Adjustments for 2021 medical fee schedule changes account for date-of-service nature of changes
- Claim Settlement Rate-Adjusted Paid
 - Best with clear evidence of changes in claim settlement rates affecting loss development
 - ★ Improved projection during periods of significant settlement rate change
 - ★ Claim settlement rates declined during pandemic slowdown but have been moderating




Cumulative Paid Development from 12 to 108 Months





Medical Age-to-Age Factors Indexed to 1990 108 to 120 Months






Comparison of Paid and Incurred Projections for AY 2021 Medical






Cumulative Medical Development from 228 to 360 Months





Estimated Ultimate Indemnity Claim Settlement Ratios (Exhibit 11.2)





Projected Indemnity On-Level Loss Ratios under Alternative Development Methods





Projected Medical On-Level Loss Ratios under Alternative Development Methods





Review of Medical Fee Schedule Changes


- At 12/5/2019 meeting, the Committee recommended staff review updates to medical fee schedules adopted by the DWC for any significant changes impacting medical costs
- Staff has conducted initial review of fee schedule updates published by DWC through March 2022
- Staff compared change in average medical cost after updating fee schedule
- No unusual changes significantly impacting medical severities discovered from updates reviewed

Fee Schedule	Effective Date	Update Type	Impact on Medical Services
Inpatient	12/1/2021	Regular inflation update	0.4%
DMEPOS	1/1/2022	Regular inflation update	0.1%
Path/Lab	1/1/2022	Regular inflation update	< 0.1%
Physician	1/1/2022	Regular inflation update	0.5%
Outpatient	3/1/2022	Regular inflation update	0.4%



Average Wage Level Change Forecast (Exhibit 5.1)

As of March 2022



Average Annual Adjusted Wage Change Projection from 2019:


9/1/2021 Filing: 2.9%

4/14/2022 Agenda: 4.7%



Estimated Accident Year 2020 Intra-Class Indemnity Claim Frequency Changes Excluding COVID-19 Claims (Exhibit 12 Updated)

As of December 31, 2021




9/1/2021 Filing Projected:
12 Month Aggregate Claim Counts / Statewide Employment

Preliminary USR Data from 2019 Policies:
USR Claim Counts / Exposure at Adjusted 2021 Wage Level




Estimated Accident Year 2021 Intra-Class Indemnity Claim Frequency Changes Excluding COVID-19 Claims (Exhibits 6.1 and 12 Updated)






Changes in 12-Month Indemnity Claim Counts and Employment Levels






Estimated 2019 to 2021 Intra-Class Indemnity Claim Frequency Changes Excluding COVID-19 Claims






Estimated 2021 to 9/1/2023 Intra-Class Indemnity Claim Frequency Projections Excluding COVID-19 Claims






Indemnity Claim Frequency Indexed to 2005





Projected Changes in On-Level Indemnity Severity (Exhibit 6.2)



Annual Exponential Trend Based on:

1990 to 2021: 0.9%


2005 to 2021: -1.2%

2017 to 2021: 2.1%

Agenda Selected: 1.0%



Ultimate Indemnity per Indemnity Claim





Projected Changes in On-Level Medical Severity (Exhibit 6.4)



Annual Exponential Trend Based on:

1990 to 2021 (including MCCP): 4.9%


2005 to 2021: 1.4%

2017 to 2021: 1.5%

Agenda Selected: 1.0%




Ultimate Medical per Indemnity Claim





Policy Year 2023 – Estimated Medical Paid by Year





Alternative Trending Methodologies (Item AC22-04-02)

- Separate Frequency & Severity Trends Projections
 - Best during periods when loss ratios are volatile
 - ★ Frequency and severity are affected by differing underlying forces
 - ★ Allows for separate assumptions and judgment about future trends
 - ★ Assumes frequency & severity not highly correlated
 - Performed well during 2002-2004 reform and SB 863 transition periods but not post-reform periods
 - Performed well in most recent study of trending methods
- Loss Ratio Trend Projections
 - Best during periods with stable loss ratio trends or when frequency and severity are highly correlated
 - Rely on accurate on-leveling adjustments
 - Performed well during post-2002 to 2004 reform period
 - ★ Did not perform well during 2002 to 2004 reform and SB 863 transition periods when trends change
 - Generally not as accurate as frequency & severity method in most recent trending study
 - Recent trends have moderated with SB 863 & SB 1160 reforms
 - ★ Unclear whether current loss ratio trends will continue into post-COVID-19 environment



Projected On-Level Indemnity Loss Ratios

As of December 31, 2021 0.450 Latest Year Claim Settlement Rate-Adjusted Paid Development Method Frequency (w/o CII Forecast) & 1% Severity Trends Applied to 2019 and 2021 Frequency (Incl. CII Forecast from 2019) & 1% Severity Trends Applied to 2019 and 2021 0.400 5-year Exponential Loss Ratio Trend Applied to 2019 and 2021 0.350 0.299 0.293 0.300 0.274 0.288 Annual Exponential Trend Based on: 0.268 0.250 1990 to 2021: -0.4% 2017 to 2021: 1.8%


1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

Accident Year



0.200


Projected On-Level Medical Loss Ratios








Projected On-Level Total Loss Ratios under Alternative Trending Methods – Years Used






Projected On-Level Total Loss Ratios under Alternative Trending Methods – Frequency Projections





Projected On-Level Total Loss Ratios under Alternative Trending Methods – Severity Projections






Projected On-Level Indemnity Loss Ratios under Alternative Trending Methods





Projected On-Level Medical Loss Ratios under Alternative Trending Methods






05

9/1/2022 Filling – COVID-19 Claim Cost Projection




COVID-19 Workers' Compensation Claims Relative to Statewide Infections






COVID-19 Share of Indemnity Claims







Projected Cost of COVID-19 Claims 1/1/21 Filing Vs Estimated Actual — Insured Employers Only





Summary of Leading Published COVID-19 Forecasts

As of April 8, 2022

 Overall, expect fewer deaths from COVID-19 in 2022 than in each of the two previous years mostly due to greater population immunity

Source	Projection for U.S.	Projection for California	Ratio of Projected to Actual in California
Institute of Health Metrics and Evaluation (IHME)	52K deaths (March through July 2022)	4,500 deaths (March through July 2022)	38% of actual deaths in the same period in 2021*
The Rockefeller Foundation (intermediate scenario)	30K to 100K deaths (next 12 months)	3,600 to 12K deaths (next 12 months)	11% to 35% of actual deaths in the preceding 12 months**

Key Considerations


- New variants
- Greater population immunity due to vaccination, booster and infections
- Higher level of immunity among healthcare and frontline workers
- Changes in mitigation measures and work from home → changes in COVID-19 exposure
- Long COVID
- COVID-19 therapeutics



^{*} The ratio was comparing the IHME's projected deaths from March through July of 2022 in California to the actual deaths from March through July of 2021 in California

^{**} The ratio was comparing the projected deaths by Rockefeller Foundation from March 2022 through March 2023 in California to the actual deaths from March 2021 through March 2022 in California. Source: Rockefeller Foundation's Report: https://www.rockefellerfoundation.org/report/getting-to-and-sustaining-the-next-normal-a-roadmap-for-living-with-covid/; IHME's projections: https://covid19.healthdata.org/united-states-of-america?view=cumulative-deaths&tab=trend

Estimated Cost of COVID-19 Claims as % of Total Losses & LAE





06

9/1/2022 Filling – Loss Adjustment Expense Experience Review




Summary of Preliminary ULAE Projection

- ULAE projection excludes COVID-19 claims
- CY 2020 ULAE is not used
 - May be distorted by pandemic
 - Unable to separate ULAE on COVID-19 claims from other ULAE amounts
- ULAE projection methodologies consistent with 9/1/2021 Filing
 - Average of open count-based method projection and recent CY ULAE to loss ratios
 - Average of CY 2018 and 2019 ULAE is used
 - ULAE projection preliminary as projected ratios are impacted by frequency and loss projections



Ratios of Paid ULAE to Paid Losses (Exhibit 1)






ULAE Projection Methodology Open Indemnity Claim Count-based Projection

- Open Indemnity Claims at Beginning of Calendar Year
 - Projected using WCIRB frequency forecasts and recent reporting and closure patterns
 - Open claims by AY projected using latest incremental claim settlement pattern
 - Frequency forecasts consistent with those used for loss projection
 - COVID-19 claims excluded
- Calendar Year Paid ULAE per Open Indemnity Claim
 - Data based on private insurers only
 - Future values projected using selected wage level changes
- Projected 9/1/2022 to 8/31/2023 Policy Inception Period ULAE
 - Trend to future CY based on average of CYs 2018 & 2019
 - (# of open indemnity claims) X (paid ULAE per open indemnity claim)
 - Use weighted average of CY in policy period (6%/72%/22% to 2022/2023/2024)
 - Paid ULAE per open claim projected out 3 years to approx. average ULAE payment date on claims



- Loss Adjustment Expense Experience Review 9/1/2022 Filing


Paid ULAE per Open Indemnity Claim – Private Insurers (Exhibit 3.5)





- Loss Adjustment Expense Experience Review 9/1/2022 Filing

Projections of ULAE to Loss





Summary of Preliminary ALAE and MCCP Projections

- Data is through December 31, 2021 with COVID-19 claims excluded
- Methodology is generally consistent with 9/1/2021 Filing
- Development is projected based on the latest year
 - ALAE development includes adjustment for changes to claim settlement rates
- Projection based on frequency and severity trends applied to accident years 2019 and 2021
- Adjustment to ALAE for the impact of SB 1160 updated with latest ALAE payment pattern
- ALAE and MCCP projections preliminary as projected ratios are impacted by frequency and loss projections




Paid ALAE Development – Private Insurers (Exhibit 8.1)





Cumulative Paid ALAE Development from 12 to 90 Months





ALAE Projection Methodology

- Accident Year Ultimate Indemnity Claim Counts
 - Latest year development
 - Projected using same frequency forecasts as loss projection
- Accident Year Ultimate ALAE per Indemnity Claim
 - Data based on private insurers only
 - Latest year development with adjustment for changes in claim settlement rates and inverse power curve tail
 - Projected using average of ultimate ALAE per indemnity claim and incremental paid ALAE per open indemnity claim for both long-term and short-term periods
- Projected 9/1/2022 to 8/31/2023 Policy Inception Period ALAE
 - (Projected # of ultimate indemnity claims) X (projected ultimate ALAE per indemnity claim)
 - Projection from AY 2019 and 2021
 - Initial projected ratio reduced for lien savings from SB 1160 & AB 1244 not yet significantly reflected in emerging ALAE costs
 - Full impact is -11.2% based on 70% reduction in lien filings
 - Tempered by 75% based on impact already emerging



Adjustment to ALAE Development for Claim Settlement Rate Changes

		As of 12/31/2021		
Age (AY @12/31/21)	(1) Age-to-Age Adjustment	(2) Settlement Rate Point Change	(3) Unadjusted Age-to-Age Factor	(4) Adjusted Age-to-Age Factor
72 (2016)	-1.1%	0.3	1.044	N/A
60 (2017)	-0.5%	0.1	1.069	N/A
48 (2018)	-0.4%	-1.2	1.114	N/A
36 (2019)	-0.6%	-2.3	1.227	1.245
24 (2020)	-0.9%	-1.2	1.573	N/A
12 (2021)	-3.4%	1.1	3.945	N/A

⁽¹⁾ Adjustment per 1 point of claim settlement rate change, from 2019 and 2020 studies, adjusted to 12/31 evaluations




^{(2), (3)} based on WCIRB aggregate financial data

 $^{(4) = [(1) \}times (2) + 1.0] \times (3)$ if (2) is greater than 1.5 in absolute value

Projected Changes in Ultimate ALAE Severity for Private Insurers (Exhibit 6)

As of December 31, 2021



Annual Exponential Trend Based on:


2008 to 2021: -0.4%

2017 to 2021: 1.4%



Change in Incremental Paid ALAE per Open Indemnity Claim for Private Insurers (Exhibit 7)

As of December 31, 2021



Annual Exponential Trend Based on:


2008 to 2021: 2.9%

2017 to 2021: -0.1%

4/14/2022 Agenda Selected ALAE Severity Trend: 1.0%



Ultimate ALAE per Indemnity Claim for Private Insurers





Experience Review - Loss Adjustment Expense 9/1/2022 Filing


Adjustment for SB 1160 & AB 1244 Lien Reforms in ALAE

AY & Age	Estimated % of 168 Mon. ALAE Paid	Estimate Reflected in 9/1/2021 Filing (70% Reduction)
2018 (48 Months)	73%	
2017 (60 Months)	81%	
Average	77%	
Selected Tempering	75%	60%
Tempered Adjustment to ALAE (-11.2% Full)	-2.8%	-4.5%



- Loss Adjustment Expense Experience Review 9/1/2022 Filing

Projections of ALAE (Excluding MCCP) to Loss





Paid MCCP Development (Exhibit 14.2)






MCCP Projection Methodology

- MCCP methodology based on that for ALAE
 - Statewide data used
 - Development based on the latest paid MCCP through 120 months and paid medical after 120 months
 - Trend based on average changes in CY MCCP per open claim and ultimate AY MCCP per indemnity claim
 - Trend applied to 2019 and 2021



Calendar Year Paid MCCP per Indemnity Claims Inventory (Exhibit 13)



Annual Exponential Trend Based on:

2009 to 2020: 0.8%



Projected Ultimate MCCP per Indemnity Claim (Exhibit 12)



Annual Exponential Trend Based on:

2012 to 2021: -2.1%


2017 to 2021: -0.2%

4/14/2022 Agenda Selected MCCP Severity Trend: -1.0%



- Loss Adjustment Expense Experience Review 9/1/2022 Filing

Projections of MCCP to Loss





wcirb.com







1901 Harrison Street, 17th Floor Oakland, CA 94612 888.CA.WCIRB (888.229.2472)